Reversible T Cell Detection via Cleavable pMHC Conjugates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and isolating antigen-specific T cells rely on multimerization scaffolds with non-covalent interactions, leading to unstable pMHC conjugates and limited multiplexing potential, which complicates the identification and verification of cancer-specific T cells and requires improved pMHC multimers with controllable reversible binding.
Innovation Solution
A conjugate with a peptide/MHC (pMHC) complex covalently conjugated via its C-terminus to an enzymatically degradable spacer, allowing for specific and stable binding to TCR and/or KIR molecules, enabling reversible labeling and subsequent removal of detection moieties from target cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If non-covalent multimerization scaffolds are used to detect T cells, then the detection method is simple to implement, but the stability and reliability of pMHC conjugates deteriorates
Solution Approach 1:
The patent changes the bonding parameter from non-covalent to covalent interaction between pMHC complexes and multimerization scaffolds. This is achieved through site-specific enzymatic conjugation (e.g., sortase-mediated ligation, transglutaminase crosslinking) that forms stable covalent bonds, thereby maintaining high reliability while preserving ease of operation through standardized protocols
Solution Approach 2:
The patent creates composite structures combining pMHC complexes with multimerization scaffolds through covalent linkage. This composite approach integrates the target-specific binding capability of pMHC with the multivalent display capability of scaffolds, achieving both stability and detection functionality simultaneously
2Measurement precision
If pMHC conjugates are used for T cell detection, then the specificity of target identification is improved, but the ability to remove detection moieties from target cells deteriorates
Solution Approach 1:
The patent segments the detection system into separable components: the pMHC complex remains bound to the T cell receptor for specific detection, while the detection moiety (fluorophore, magnetic bead) is attached via a cleavable linker. This allows enzymatic cleavage (e.g., by matrix metalloproteinases, phospholipases) to remove only the detection moiety, preserving measurement precision while enabling reversibility
Solution Approach 2:
The patent introduces a cleavable linker as an intermediary between the pMHC complex and the detection moiety. This intermediary component can be specifically degraded by endogenous enzymes or added proteases, allowing controlled removal of detection moieties without affecting the specific binding between pMHC and T cell receptors
3Productivity
If multiple pMHC conjugates are used for multiplexing, then the productivity of T cell identification is improved, but the complexity of conjugate preparation and stability control deteriorates
Solution Approach 1:
The patent creates universal multimerization scaffolds that can bind multiple different pMHC complexes through standardized covalent attachment sites. This universal platform allows researchers to prepare multiple specialized conjugates (each with different pMHC specificities) using the same scaffold and conjugation protocol, thereby increasing productivity while managing complexity through standardization
Solution Approach 2:
The patent standardizes the conjugation parameters (enzyme type, buffer conditions, temperature, time) across different pMHC-scaffold combinations. This parameter standardization enables batch preparation of multiple conjugate types with consistent quality, improving productivity while reducing the complexity of preparing and controlling each individual conjugate
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the specificity and stability of pMHC conjugates, facilitating efficient detection and isolation of T cells while allowing for multiple labeling cycles and improved throughput in identifying anti-tumor reactive T cells.
Implementation Method 1
the degradable spacer may be enzymatically degraded, thereby cleaving the detection moieties X from the labeled target moieties
Data Source
Figure 1
Figure 2
Figure 3a~3b
AI summary
The invention is directed to a Conjugate for labelling a target moiety on a cell, characterized by general formula (II): Xo - P - Ym, with Y : MHC-complex targeting TCR molecules, P : enzymatically degradable spacer, X : detection moiety, o : integer between 5 and 25, m : integer between 2 and 1000, wherein X and P; P and Y are covalently bound to each other and Y is bound to P via the C-terminus.